Tuesday, July 09, 2019
This wonderful blue drug is found to be the immense economical treatments available for easing male dysfunction known as Impotence. viagra 20mg in india 100mg is a medicine which is approved by FDA and so any company will be able to produce the same medicine by the same name. Recent studies published in the prestigious purchasing viagra in canada Neuron American journal, showed that, in people with autism, this balance is paralyzed. I know, how boring of me to say appalachianmagazine.com order cheap cialis to turn her on and she can get satisfaction in lovemaking. This mechanism helps blood to last in the male reproductive organ that is needed in order to male reproductive system to do all it duties.Then in the greatest step, buy viagra in india professional increases the deposition from the nitric oxide in blood which more supports in making muscles of penis area elastic.
DrugName : oxymetazoline hydrochloride
Aclaris Therapeutics, Inc., a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,335,391 covering methods of treating facial erythema associated with rosacea using a 1.0% w/w oxymetazoline hydrochloride composition. This issued U.S. Patent will be listed in the Orange Book for RHOFADE and is set to expire in June 2035. RHOFADE is the first a1A adrenoceptor agonist approved for the topical treatment of persistent facial erythema (redness) associated with rosacea in adults, which is estimated to affect nearly 16 million people in the U.S.
The patent contains 37 claims directed to methods of treating facial erythema associated with rosacea. The claimed methods include topically administering once daily on the face of the patient a composition comprising 1.0% w/w oxymetazoline hydrochloride as the sole active ingredient.
The RHOFADE patent estate includes five other Orange Book listed U.S. patents expiring between January 2024 and June 2035, as well as several pending U.S. patent applications. Internationally, RHOFADE is covered by several issued European patents, including European Patent No. EP2675449, granted on April 24, 2019, which is directed to the use of oxymetazoline cream for the topical treatment of inflammatory lesions associated with rosacea. RHOFADE is also covered by issued patents in Japan, South Korea, Australia, and several other major foreign countries.
About RHOFADE
RHOFADE cream 1% is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults.
“Aclaris continues to expand its intellectual property estate and we are pleased to add a 6th Orange Book listable patent to the intellectual property portfolio covering RHOFADE. This U.S. patent, together with the recently granted European patent, augment our strong worldwide intellectual property portfolio covering RHOFADE,” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris.